Quick View
| Metric | Current Period | Same Period of Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥129.50B | ¥108.00B | +19.9% |
| Operating Income | ¥18.19B | ¥20.40B | −10.8% |
| Profit Before Tax | ¥18.29B | ¥11.93B | +53.3% |
| Net Income | ¥17.00B | ¥11.21B | +51.7% |
| ROE | 4.2% | 3.8% | - |
Executive Summary
In Q1 (IFRS), the Company posted a mixed set of results, with revenue growth and a decline in operating income, alongside revenue growth and an increase in net income. Profitability at the operating level deteriorated due to a higher cost ratio, while bottom-line profit increased substantially as a result of improved non-operating income and expenses. Revenue was ¥129.495B (+19.9% year on year), operating income was ¥18.188B (-10.8%), profit before tax was ¥18.295B (+53.3%), and net income attributable to owners of the parent (hereinafter, “net income”) was ¥16.997B (+51.7%). The increase in revenue was driven by the consolidation of the operating structure for the Company’s core U.S. products. The transition to a single business segment was also implemented from the current period. The decline in operating income was primarily attributable to a lower gross margin resulting from the increase in the cost ratio, while the increase in net income resulted from a substantial reduction in finance costs and the conversion of equity-method investment losses into profits. The differing directions of operating income and net income were the defining characteristics of these results.
Factors Affecting Performance
【Revenue】Revenue was ¥129.495B, representing a year-on-year increase of +19.9%. From Q1, the assets, including patent rights, related to the three core U.S. products were transferred from a wholly owned subsidiary to the Company itself. The Company consequently changed to an operating structure under which the allocation of management resources and performance evaluation are conducted on an integrated basis within a single Pharmaceutical Business segment. Accordingly, disclosure of the breakdown by segment has been omitted.
【Profit and Loss】Cost of sales increased by +39.3% year on year to ¥61.41B, while the gross margin declined to 52.6% from 59.2%, a decrease of -6.6pt. Selling, general and administrative expenses were ¥39.24B (+10.1%), and research and development expenses were ¥11.43B (8.8% of revenue). Although both grew more slowly than revenue (+19.9%), they were insufficient to absorb the decline in gross margin, resulting in a 10.8% year-on-year decrease in operating income to ¥18.19B. Meanwhile, finance costs fell sharply from ¥9.05B in the previous year to ¥2.09B, and equity-method investment gains and losses turned from a loss of -¥0.64B in the previous year to a gain of +¥0.44B. Consequently, profit before tax increased by +53.3% to ¥18.29B. The effective tax rate remained low at 7.1% compared with 6.1% in the previous year, and net income increased substantially by +51.7% to ¥16.997B. In conclusion, the results represent a coexistence of revenue growth with lower profit on an operating-income basis and revenue growth with higher profit on a net-income basis, with the latter driven by non-operating factors.
Key Financial Indicators
【Profitability】The operating margin declined to 14.0% from 18.9%, a decrease of -4.8pt, while the gross margin declined to 52.6% from 59.2%, a decrease of -6.6pt. In contrast, the net profit margin improved to 13.1% from 10.4%, an increase of +2.8pt, indicating divergent profitability trends at the operating and bottom-line levels.【Cash Flow Quality】Operating cash flow (OCF) was -¥7.44B, substantially below net income of ¥16.997B, indicating that cash-generation capacity was not commensurate with the reported profit level.【Investment Efficiency】ROE was 4.2%, based on a DuPont decomposition comprising a net profit margin of 13.1%, total asset turnover of 0.153x (quarterly basis), and financial leverage of 2.07x. The low total asset turnover constrained ROE.【Financial Soundness】The equity ratio improved to 48.4% from 36.4%, an increase of +12.0pt, while long-term borrowings were reduced by -33.2% year on year to ¥119.66B. Goodwill was ¥214.39B, equivalent to 52.5% of equity attributable to owners of the parent of ¥40.86B, indicating a high degree of reliance on goodwill in the asset structure.
Cash Flow Analysis
Operating cash flow was -¥7.44B, compared with -¥0.19B in the previous year, representing a substantial divergence from net income of ¥16.997B. The primary factor was a deterioration in working capital: trade receivables increased by ¥7.28B, trade payables decreased by ¥8.73B, and other working capital items made a negative contribution of -¥28.86B, while inventories decreased by ¥5.88B and contributed positively to cash flow. Investing cash flow was +¥0.05B, approximately balanced, with capital expenditures of ¥0.66B remaining below depreciation and amortization expense of ¥4.899B. As a result, free cash flow was -¥7.39B. Financing cash flow was strongly positive at +¥39.15B, primarily comprising ¥96.88B of funding raised through the issuance of new shares and repayment of ¥60B in long-term borrowings. Cash and cash equivalents increased by +¥32.33B from ¥44.31B at the beginning of the period to ¥76.64B at period-end; however, this increase resulted from capital financing rather than operating activities.
Earnings Quality
The increase in net income was achieved through an improvement in non-operating income and expenses despite a decline in the operating margin (-4.8pt), and this distinction is important when assessing earnings quality. The substantial decrease in finance costs from ¥9.05B in the previous year to ¥2.09B, together with the conversion of equity-method investment losses from -¥0.64B in the previous year into gains of +¥0.44B, was the primary driver of the +53.3% increase in profit before tax. These factors include recurring but temporary improvement drivers separate from the profitability of the core business. In addition, OCF of -¥7.44B was substantially below net income of ¥16.997B, indicating a significant divergence between accrual-based earnings and cash flows, which warrants attention from an earnings-quality perspective. Comprehensive income was ¥18.91B, exceeding net income by ¥1.91B. This difference was primarily attributable to foreign currency translation adjustments for foreign operations of +¥1.80B, representing a foreign-exchange factor distinct from business operating performance.
Earnings Forecast and Guidance
Progress against the full-year earnings forecast was 24.0% for revenue (¥129.495B/¥540B), 20.2% for operating income (¥18.188B/¥90B), and 22.1% for net income (¥16.997B/¥77B), all below the 25% benchmark for even quarterly progress. Operating income had the lowest progress rate, at 20.2%, while the full-year plan itself anticipates a year-on-year decline of -16.2%. Although the earnings forecast was revised during the current quarter, there was no revision to the dividend forecast. The progress rates suggest a plan weighted toward the second half of the fiscal year, with the extent of gross-margin recovery and expense trends expected to determine future progress.
Shareholder Returns
The dividend forecast for the fiscal year ending March 2027 is currently undetermined. Dividend payments during the current quarter were ¥0.001B, remaining at the same negligible level as in the same period of the previous year, while share repurchases were also limited to less than ¥0.001B. During the current period, the Company raised ¥96.88B through the issuance of new shares, suggesting that strengthening the financial foundation is being prioritized over shareholder returns.
Risk Factors
-
Goodwill impairment risk: Goodwill was ¥214.39B, reaching 52.5% of equity attributable to owners of the parent of ¥40.86B. Depending on future profitability trends, impairment recognition could affect net assets, making this an item requiring monitoring.
-
Quality of operating cash flow: OCF was -¥7.44B, representing a substantial divergence from net income of ¥16.997B. The primary factors were deterioration in working capital, including an increase of +¥7.28B in trade receivables and a decrease of -¥8.73B in trade payables. Ongoing monitoring of the relationship between earnings and cash generation is required.
-
Progress toward achieving the full-year plan: The full-year progress rate for operating income was 20.2%, below the standard quarterly progress benchmark of 25%. The gross margin declined by -6.6pt from the previous year, and achieving the full-year plan, which anticipates a year-on-year decline of -16.2%, will require profitability to improve from the second half onward.
Industry Benchmarks (For Reference; Compiled by the Company)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 14.0% | 17.5% (6.9%–23.1%) | −3.5pt |
| Net Profit Margin | 13.1% | 7.0% (2.5%–15.6%) | +6.1pt |
The operating margin was below the industry median, while the net profit margin was substantially above the median, indicating that the Company’s positioning within the industry differs depending on the stage of the income statement.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (Year on Year) | 19.9% | 9.8% (2.9%–13.0%) | +10.0pt |
The revenue growth rate was substantially above the industry median, demonstrating a high rate of revenue growth within the industry.
Source: Compiled by the Company
Key Takeaways from the Financial Results
-
Although the decline in gross margin (-6.6pt) resulted in a -10.8% decrease in operating income, net income increased by +51.7% due to lower finance costs and improved equity-method investment gains and losses. The differing trends on an operating-income basis and a net-income basis demonstrate the need to distinguish between the profitability of the core business and non-operating factors.
-
The equity ratio improved to 48.4% from 36.4% in the previous year as a result of the issuance of new shares (¥96.88B) and repayment of ¥60B in long-term borrowings. Although financial soundness improved, the fact that goodwill accounted for 52.5% of equity attributable to owners of the parent remains an observation point when assessing B/S quality.
-
OCF was -¥7.44B, below net income, while progress against the full-year plan was also below the standard quarterly benchmark, at 24.0% for revenue, 20.2% for operating income, and 22.1% for net income. Normalization of working capital and recovery in profitability during the second half are key points to watch in assessing achievement of the full-year plan.
Theoretical Share Price (Reference Value)
This is a reference range mechanically calculated solely from publicly available data using a residual income model (Ohlson-type, with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.
| Scenario | Theoretical Share Price |
|---|---|
| bear | ¥1,137 |
| base | ¥1,239 |
| bull | ¥1,288 |
| Calculation Assumption | Value |
|---|---|
| Book Value per Share (BPS) | ¥911 |
| Adjusted Forecast EPS | ¥187.6 |
| Cost of Equity r | 9.15% (10-year government bond 2.65% + equity risk premium 6.00% + size premium 0.50%) |
| Residual Income Persistence Coefficient ω / Explicit Forecast Period | 0.62 / 5 years |
| Assumed Payout Ratio | 30.0% |
| Forecast EPS Confidence Adjustment | ×1.085 (based on the actual guidance achievement rate of peer companies in the same industry) |
| Implied PBR / PER | 1.36x / 6.6x |
Sensitivity: ¥1,204–¥1,277 at ±1% for the cost of equity, and ¥1,231–¥1,253 at ±0.1 for ω.
Notes:
- Goodwill represents a high proportion of net assets, and the assumptions would change substantially if impairment were recognized.
- Net assets as of the end of the quarter are used; there is a timing difference between these figures and the full-year forecast.
(Calculation model: Residual income model / Interest rate reference month: 2026-06 / This figure does not predict or guarantee the future share price)
This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional adviser as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
Sumitomo Pharma delivered strong Q1 FY2027 revenue and net-profit growth, but underlying operating-margin and cash-conversion trends were weaker. Revenue rose 19.9% year on year to ¥129.5bn. Gross profit increased 6.6% to ¥68.1bn. Operating income nevertheless fell 10.8% to ¥18.2bn as cost of sales increased 39.2%, SG&A increased 10.0%, and R&D expense increased 39.8% to ¥11.4bn. The gross margin contracted to 52.6% from 59.2%, a 660bp decline. Operating margin contracted to 14.0% from 18.9%, a 490bp decline, although it remains within the industry benchmark range for a good profitability profile. Net income rose 51.7% to ¥17.0bn, lifting net margin to 13.1% from 10.4%, a 270bp expansion. The net-income outperformance was primarily below the operating line: finance costs declined sharply to ¥2.1bn from ¥9.1bn, finance income rose to ¥2.2bn from ¥0.6bn, and equity-method income turned positive at ¥0.4bn from a ¥0.6bn loss. The 7.1% effective tax rate also supported net income. Accordingly, the improvement in net profit does not fully represent an improvement in core operating earnings. Q1 operating cash flow was negative ¥7.4bn despite ¥17.0bn of net income, resulting in an OCF/net-income ratio of negative 0.44x. This divergence reflects substantial working-capital outflows, particularly other working-capital items, receivables, and payables. Free cash flow was negative ¥7.4bn, despite restrained capital expenditures of ¥0.7bn. The balance sheet was materially recapitalized through ¥97.2bn of equity issuance, while the company repaid ¥60.0bn of long-term borrowings. Cash increased to ¥76.6bn and the equity ratio improved to 48.4% from 36.4% a year earlier. Management's FY2027 guidance implies Q1 progress of 24.0% for revenue, 20.2% for operating income, and 22.1% for net income, with profit progress below the standard 25% first-quarter run rate. The key forward implication is that sustaining the full-year earnings plan requires a recovery in gross and operating margins as well as conversion of reported profits into operating cash flow.
Profitability Analysis
Annualized DuPont ROE is 16.6%, comprising a 13.1% net-profit margin, 0.613x annualized asset turnover, and 2.07x financial leverage. The net margin is above the 10% benchmark for excellent profitability, while the annualized ROE is also above the 15% excellent threshold. Financial leverage is the principal amplifier of shareholder returns, although its contribution should be assessed alongside the large equity issuance during the quarter. Core margin movement was adverse: gross margin declined 660bp year on year to 52.6%, reflecting cost of sales growth of 39.2%, materially above revenue growth of 19.9%. Operating margin fell 490bp to 14.0%, because SG&A plus R&D grew 16.8%, faster than revenue, while gross-profit growth was only 6.6%. R&D spending reached ¥11.4bn, equal to 8.8% of revenue, up from 7.6% a year earlier. This is below the 15-20% innovator-pharma R&D-intensity benchmark, while the sharp year-on-year increase indicates that management is investing more heavily in development activity. The operating-income decline therefore reflects both weaker gross-profit conversion and higher development expenditure. The 51.7% rise in net income is not matched by operating profit, making the improvement less indicative of recurring operating leverage. Finance income of ¥2.2bn exceeded finance costs of ¥2.1bn, compared with a substantial net finance-cost burden in the prior-year quarter. The 0.929 tax burden and 1.006 interest burden were favorable contributors to annualized ROE. The sustainability of the Q1 net margin depends on retaining these favorable financial-income and finance-cost dynamics while restoring pharmaceutical product economics.
Growth Assessment
Revenue growth of 19.9% to ¥129.5bn was robust, but its translation into gross profit was limited by the 39.2% increase in cost of sales. Gross profit rose only 6.6%, substantially trailing sales growth. SG&A rose 10.0% and R&D rose 39.8%, resulting in a 10.8% decline in operating income. The business is now managed as a single pharmaceutical segment following the transfer of rights related to key US products to the parent-company operating structure; therefore, group-level earnings trends are the relevant measure of core performance. FY2027 guidance calls for revenue of ¥540.0bn, operating income of ¥90.0bn, and net income attributable to owners of ¥77.0bn. Q1 revenue progress is 24.0%, broadly aligned with the 25% seasonal benchmark. Operating-income progress is 20.2%, 4.8 percentage points below the benchmark, and net-income progress is 22.1%, 2.9 percentage points below it. Neither profit-progress deviation exceeds 10 percentage points, but the first-quarter shortfall underscores the need for later-period margin improvement. Full-year guidance implies a 16.7% operating margin, above the Q1 14.0% margin, requiring a 270bp improvement over the remainder of the fiscal year. The company has revised its earnings forecast, increasing the importance of monitoring subsequent-quarter execution against the updated plan. Pharmaceutical growth remains exposed to product-life-cycle dynamics, regulatory outcomes, pricing conditions, and the commercial performance of key products.
Financial Health
Liquidity is adequate but not excessive. The current ratio is 1.21x, above the 1.0x warning threshold but below the 1.5x healthy benchmark. The quick ratio is approximately 0.91x, based on cash, receivables, and other current financial assets relative to current liabilities, indicating some reliance on inventory realization and continued cash inflows to cover short-term obligations. Cash and cash equivalents of ¥76.6bn cover short-term loans of ¥41.0bn by 1.87x. Debt/capital is low at 9.1%, reflecting the major equity issuance and the repayment of ¥60.0bn in long-term borrowings. However, 100% of reported interest-bearing debt is short term, which creates a refinancing-risk consideration despite cash coverage. The disclosed debt-to-equity ratio is 1.07x, below the 2.0x aggressive-leverage warning threshold, while the debt/capital metric points to a conservative interest-bearing-debt position. Total equity increased to ¥408.6bn from ¥292.5bn a year earlier, and the equity ratio improved by 12.0 percentage points to 48.4%. The improvement was primarily capital-market driven: the company raised ¥97.2bn through new share issuance during Q1. Noncurrent liabilities declined to ¥174.5bn from ¥240.6bn a year earlier, consistent with deleveraging. Asset quality remains a central balance-sheet consideration because goodwill represents ¥214.4bn, or 25.4% of total assets and 52.5% of equity. Intangible assets add a further ¥157.4bn, equivalent to 18.6% of total assets. Consequently, preservation of the carrying value of acquired product rights, technology, and goodwill is important to the solidity of book equity.
Notable B/S Changes
Cash and cash equivalents: +¥323.3bn (+73.0% YoY) to ¥766.4bn - liquidity improved substantially, principally supported by financing cash flow and the Q1 equity issuance. Total equity: +¥1,160.9bn (+39.7% YoY) to ¥4,085.6bn - capital strengthening was driven primarily by ¥971.8bn of owner transactions, including ¥971.8bn of new share issuance. Noncurrent borrowings: -¥593.9bn (-33.2% YoY) to ¥1,196.6bn - repayment of ¥600.0bn of long-term borrowings reduced long-term financing exposure. Goodwill: ¥2,143.9bn, representing 25.4% of total assets and 52.5% of equity - the asset is unusually large relative to equity and makes future impairment testing material to book-value preservation. Intangible assets: ¥1,573.6bn, representing 18.6% of total assets - acquired and product-related intangible values remain a major component of the asset base and should be assessed alongside future product performance.
Cash Flow Quality
Cash-flow quality was weak in Q1. Operating cash flow was negative ¥7.4bn versus net income of ¥17.0bn, producing an OCF/net-income ratio of negative 0.44x, materially below the 0.8x concern threshold. Free cash flow was negative ¥7.4bn after capital expenditures of ¥0.7bn. The principal source of the earnings-to-cash divergence was working capital rather than fixed-asset investment. Receivables increased by ¥7.3bn, producing a cash outflow. Payables decreased by ¥8.7bn, also creating a cash outflow. Other working-capital movements were a substantial negative ¥28.9bn. Inventory decreased by ¥5.9bn and provisions increased by ¥5.2bn, partly offsetting these outflows but not sufficiently. Receivable days of 98 and inventory days of 118 are both elevated relative to the stated alert thresholds. The 144-day cash-conversion cycle is also long, increasing sensitivity to collection timing, inventory management, demand forecasting, and distributor or customer ordering patterns. The accruals ratio of 2.9% is within the below-5% high-quality benchmark, but it does not offset the negative operating cash generation in the quarter. Financing cash flow of ¥391.5bn was the source of the increase in cash, driven principally by the equity issuance and partly by short-term borrowing, rather than internally generated cash. Investment cash flow was modestly positive at ¥0.5bn, supported by ¥27.9bn of investment-sale and redemption proceeds, while investment purchases totaled ¥5.9bn and equity-method investment purchases totaled ¥16.7bn. Subsequent periods should demonstrate whether the current cash-flow deficit reverses as receivables are collected and working-capital outflows normalize.
Dividend Sustainability
FY2027 dividend guidance is currently undecided. Q1 dividends paid were immaterial at ¥0.01bn, and there is no reported DPS basis for calculating a dividend payout ratio. Negative free cash flow of ¥7.4bn means that dividend capacity cannot presently be evaluated on Q1 cash generation alone. Liquidity is supported by ¥76.6bn of cash and the Q1 equity raise, but sustainable shareholder distributions should ultimately be supported by recurring operating cash flow rather than external financing. The combination of negative OCF, elevated working-capital intensity, and the need to protect pharmaceutical R&D investment suggests that cash conversion is the primary item to monitor before assessing a durable dividend capacity. Treasury-share purchases were also immaterial in Q1, so no meaningful total return ratio can be derived.
Risk Assessment
Business risks include Pharmaceutical margin risk: cost of sales grew 39.2% versus 19.9% revenue growth, driving a 660bp gross-margin contraction to 52.6%., Product and pipeline risk: pharmaceutical earnings remain vulnerable to clinical-development outcomes, regulatory decisions, patent expiries, generic competition, reimbursement policy, and commercial performance of key products., Working-capital execution risk: 98-day receivables, 118-day inventory, and a 144-day cash-conversion cycle increase exposure to collection delays, channel inventory movements, and demand-forecasting errors., Operating-plan delivery risk: Q1 operating-income progress was 20.2% against the full-year forecast, below the 25% standard quarterly run rate, while the full-year plan requires a 16.7% operating margin versus 14.0% in Q1..
Financial risks include Earnings-quality alert: OCF/net income was negative 0.44x. The root cause was working-capital outflows, including ¥28.9bn of other working-capital outflows, ¥7.3bn receivable growth, and ¥8.7bn of payables reduction. The impact is that Q1 profits did not generate internal liquidity and free cash flow was negative., Refinancing-risk alert: 100% of reported interest-bearing debt is short term. Cash covers short-term loans by 1.87x and debt/capital is only 9.1%, which moderates immediate risk, but the maturity concentration requires continuing access to refinancing or use of cash., Goodwill-risk alert: goodwill equals 52.5% of equity, above the 50% warning threshold. The root cause is a balance sheet with ¥214.4bn of acquisition-related goodwill. The impact is heightened sensitivity of equity and future earnings to impairment if acquired assets or product rights underperform., Capital-structure transition risk: the Q1 increase in cash and equity was driven primarily by ¥97.2bn of new equity issuance, while long-term borrowings were repaid by ¥60.0bn. This improves solvency but indicates that balance-sheet repair and funding sources remain material to the financial profile..
Key concerns include The largest concern is divergence between core and reported earnings: operating income declined 10.8%, whereas net income rose 51.7% due largely to improved net finance income/cost and a low tax rate., The second concern is whether the operating cash-flow deficit is temporary. Continued negative conversion would limit internally funded R&D, investment, debt servicing, and distributions., The third concern is impaired-margin recovery: full-year operating-income guidance requires a meaningful improvement from the Q1 operating margin., The fourth concern is the concentration of noncurrent assets in goodwill and intangibles, totaling 44.0% of total assets..
Investment Implications
Key takeaways include Revenue momentum was strong at +19.9% year on year, but operating income fell 10.8% because gross-margin pressure and higher R&D more than offset sales growth., Net income increased 51.7%, but the improvement was supported by sharply lower finance costs, higher finance income, positive equity-method income, and a 7.1% tax rate rather than by operating-profit expansion., Annualized ROE of 16.6% and net margin of 13.1% are strong headline profitability indicators, though leverage and below-operating-line factors contribute materially., The Q1 capital raise and long-term debt repayment strengthened liquidity and capitalization, raising the equity ratio to 48.4%., Negative operating cash flow and a long cash-conversion cycle are the principal near-term quality concerns..
Metrics to watch include Gross margin and operating margin relative to Q1 levels of 52.6% and 14.0%, respectively, Revenue, operating-income, and net-income progress against FY2027 guidance of ¥540.0bn, ¥90.0bn, and ¥77.0bn, Operating cash flow and OCF/net-income conversion relative to the negative 0.44x Q1 result, Receivable days, inventory days, and cash-conversion cycle from 98 days, 118 days, and 144 days, Short-term debt refinancing and cash coverage of short-term loans, Goodwill and intangible-asset carrying values, impairment indicators, and the resulting goodwill-to-equity ratio.
Regarding relative positioning, The company combines above-benchmark annualized ROE and net margin with a balance sheet that has been significantly recapitalized. Relative to pharmaceutical profitability benchmarks, its 14.0% Q1 operating margin is good but below the >15% excellent threshold, while the 8.8% R&D intensity is below the typical 15-20% innovator-pharma range. The financial profile is less constrained by interest-bearing debt after the equity raise and long-term debt repayment, but it is more exposed than a balance sheet with lower acquisition-related assets because goodwill exceeds half of equity. Cash conversion and margin recovery are more important determinants of earnings durability than the headline Q1 net-income growth rate.